A retrospective study analyzing patients with stage III-IV ovarian cancer utilized CD68 and CD163 as M1 and M2 macrophage markers, respectively, to analyze the expression of TAMs within tumor samples. The gene discussed is CD163; the disease is ovarian cancer.